vs
海斯特耶鲁（HY）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
海斯特耶鲁的季度营收约是Revvity的1.2倍（$923.2M vs $772.1M），Revvity净利率更高（12.7% vs -5.7%，领先18.4%），Revvity同比增速更快（5.9% vs -13.5%），Revvity自由现金流更多（$161.8M vs $32.9M），过去两年Revvity的营收复合增速更高（9.0% vs -6.5%）
海斯特-耶鲁物料搬运公司通过其全资运营子公司海斯特-耶鲁集团，主要以海斯特与耶鲁品牌在全球范围设计研发、生产销售全系列叉车，并提供售后配件与相关服务。该公司2002年起就在NACCO工业集团内独立运营，最终于2012年从NACCO分拆独立。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
HY vs RVTY — 直观对比
营收规模更大
HY
是对方的1.2倍
$772.1M
营收增速更快
RVTY
高出19.4%
-13.5%
净利率更高
RVTY
高出18.4%
-5.7%
自由现金流更多
RVTY
多$128.9M
$32.9M
两年增速更快
RVTY
近两年复合增速
-6.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $923.2M | $772.1M |
| 净利润 | $-52.5M | $98.4M |
| 毛利率 | 14.2% | — |
| 营业利润率 | -4.0% | 14.5% |
| 净利率 | -5.7% | 12.7% |
| 营收同比 | -13.5% | 5.9% |
| 净利润同比 | -609.7% | 3.9% |
| 每股收益（稀释后） | $-2.97 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HYRVTY
| Q4 25 | $923.2M | $772.1M | ||
| Q3 25 | $979.1M | $698.9M | ||
| Q2 25 | $956.6M | $720.3M | ||
| Q1 25 | $910.4M | $664.8M | ||
| Q4 24 | $1.1B | $729.4M | ||
| Q3 24 | $1.0B | $684.0M | ||
| Q2 24 | $1.2B | $691.7M | ||
| Q1 24 | $1.1B | $649.9M |
净利润HYRVTY
| Q4 25 | $-52.5M | $98.4M | ||
| Q3 25 | $-2.3M | $46.7M | ||
| Q2 25 | $-13.9M | $53.9M | ||
| Q1 25 | $8.6M | $42.2M | ||
| Q4 24 | $10.3M | $94.6M | ||
| Q3 24 | $17.2M | $94.4M | ||
| Q2 24 | $63.3M | $55.4M | ||
| Q1 24 | $51.5M | $26.0M |
毛利率HYRVTY
| Q4 25 | 14.2% | — | ||
| Q3 25 | 15.9% | 53.6% | ||
| Q2 25 | 17.6% | 54.5% | ||
| Q1 25 | 19.5% | 56.5% | ||
| Q4 24 | 19.4% | — | ||
| Q3 24 | 19.0% | 56.3% | ||
| Q2 24 | 22.2% | 55.7% | ||
| Q1 24 | 22.3% | 54.6% |
营业利润率HYRVTY
| Q4 25 | -4.0% | 14.5% | ||
| Q3 25 | 0.2% | 11.7% | ||
| Q2 25 | -0.9% | 12.6% | ||
| Q1 25 | 2.3% | 10.9% | ||
| Q4 24 | 3.0% | 16.3% | ||
| Q3 24 | 3.3% | 14.3% | ||
| Q2 24 | 8.2% | 12.4% | ||
| Q1 24 | 7.9% | 6.8% |
净利率HYRVTY
| Q4 25 | -5.7% | 12.7% | ||
| Q3 25 | -0.2% | 6.7% | ||
| Q2 25 | -1.5% | 7.5% | ||
| Q1 25 | 0.9% | 6.4% | ||
| Q4 24 | 1.0% | 13.0% | ||
| Q3 24 | 1.7% | 13.8% | ||
| Q2 24 | 5.4% | 8.0% | ||
| Q1 24 | 4.9% | 4.0% |
每股收益（稀释后）HYRVTY
| Q4 25 | $-2.97 | $0.86 | ||
| Q3 25 | $-0.13 | $0.40 | ||
| Q2 25 | $-0.79 | $0.46 | ||
| Q1 25 | $0.48 | $0.35 | ||
| Q4 24 | $0.57 | $0.77 | ||
| Q3 24 | $0.97 | $0.77 | ||
| Q2 24 | $3.58 | $0.45 | ||
| Q1 24 | $2.93 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | $251.9M | — |
| 股东权益账面价值 | $472.0M | $7.3B |
| 总资产 | $2.0B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.53× | — |
8季度趋势，按日历期对齐
现金及短期投资HYRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
总债务HYRVTY
| Q4 25 | $251.9M | — | ||
| Q3 25 | $252.2M | — | ||
| Q2 25 | $245.2M | — | ||
| Q1 25 | $242.6M | — | ||
| Q4 24 | $241.9M | — | ||
| Q3 24 | $247.4M | — | ||
| Q2 24 | $248.5M | — | ||
| Q1 24 | $239.7M | — |
股东权益HYRVTY
| Q4 25 | $472.0M | $7.3B | ||
| Q3 25 | $536.0M | $7.4B | ||
| Q2 25 | $544.7M | $7.6B | ||
| Q1 25 | $510.0M | $7.6B | ||
| Q4 24 | $475.1M | $7.7B | ||
| Q3 24 | $529.9M | $7.9B | ||
| Q2 24 | $465.7M | $7.9B | ||
| Q1 24 | $412.1M | $7.8B |
总资产HYRVTY
| Q4 25 | $2.0B | $12.2B | ||
| Q3 25 | $2.1B | $12.1B | ||
| Q2 25 | $2.1B | $12.4B | ||
| Q1 25 | $2.1B | $12.4B | ||
| Q4 24 | $2.0B | $12.4B | ||
| Q3 24 | $2.2B | $12.8B | ||
| Q2 24 | $2.1B | $13.4B | ||
| Q1 24 | $2.1B | $13.4B |
负债/权益比HYRVTY
| Q4 25 | 0.53× | — | ||
| Q3 25 | 0.47× | — | ||
| Q2 25 | 0.45× | — | ||
| Q1 25 | 0.48× | — | ||
| Q4 24 | 0.51× | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 0.53× | — | ||
| Q1 24 | 0.58× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $56.5M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $32.9M | $161.8M |
| 自由现金流率自由现金流/营收 | 3.6% | 21.0% |
| 资本支出强度资本支出/营收 | 2.6% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $23.6M | $509.4M |
8季度趋势，按日历期对齐
经营现金流HYRVTY
| Q4 25 | $56.5M | $182.0M | ||
| Q3 25 | $37.1M | $138.5M | ||
| Q2 25 | $28.9M | $134.3M | ||
| Q1 25 | $-36.4M | $128.2M | ||
| Q4 24 | $80.7M | $174.2M | ||
| Q3 24 | $70.1M | $147.9M | ||
| Q2 24 | $-2.5M | $158.6M | ||
| Q1 24 | $22.4M | $147.6M |
自由现金流HYRVTY
| Q4 25 | $32.9M | $161.8M | ||
| Q3 25 | $22.6M | $120.0M | ||
| Q2 25 | $15.1M | $115.5M | ||
| Q1 25 | $-47.0M | $112.2M | ||
| Q4 24 | $62.8M | $149.8M | ||
| Q3 24 | $59.9M | $125.6M | ||
| Q2 24 | $-14.7M | $136.6M | ||
| Q1 24 | $14.9M | $129.7M |
自由现金流率HYRVTY
| Q4 25 | 3.6% | 21.0% | ||
| Q3 25 | 2.3% | 17.2% | ||
| Q2 25 | 1.6% | 16.0% | ||
| Q1 25 | -5.2% | 16.9% | ||
| Q4 24 | 5.9% | 20.5% | ||
| Q3 24 | 5.9% | 18.4% | ||
| Q2 24 | -1.3% | 19.7% | ||
| Q1 24 | 1.4% | 20.0% |
资本支出强度HYRVTY
| Q4 25 | 2.6% | 2.6% | ||
| Q3 25 | 1.5% | 2.6% | ||
| Q2 25 | 1.4% | 2.6% | ||
| Q1 25 | 1.2% | 2.4% | ||
| Q4 24 | 1.7% | 3.4% | ||
| Q3 24 | 1.0% | 3.3% | ||
| Q2 24 | 1.0% | 3.2% | ||
| Q1 24 | 0.7% | 2.7% |
现金转化率HYRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | -4.23× | 3.03× | ||
| Q4 24 | 7.83× | 1.84× | ||
| Q3 24 | 4.08× | 1.57× | ||
| Q2 24 | -0.04× | 2.87× | ||
| Q1 24 | 0.43× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HY
| Sales Channel Through Intermediary | $281.7M | 31% |
| Aftermarketsales | $179.1M | 19% |
| Sales Channel Directly To Consumer | $173.6M | 19% |
| EMEAHY | $153.3M | 17% |
| Equity Method Investment Nonconsolidated Investee Or Group Of Investees | $89.0M | 10% |
| Otherrevenue | $42.4M | 5% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
